Financial Trends -- 8/10

Constellation Energy delivered a massive cash flow inflection in FY2025, swinging from ($2.5B) negative CFO in FY2024 to +$4.2B positive -- a $6.7B improvement driven by hedging book unwind. Adj. Operating EPS compounded at ~22% since FY2023, reaching $9.39 in FY2025. The nuclear fleet operates consistently above 94% capacity factor, ~4 points above industry average. Management guides to 20%+ base EPS CAGR through 2029 with no buyback assumed. Weight: 25%
FY2025 Revenue
$25.5B
+8.3% YoY
Adj. Operating EPS
$9.39
+8.3% YoY (FY2024: $8.67)
FY2025 CFO
$4.2B
vs ($2.5B) in FY2024 -- massive swing
Nuclear Capacity Factor
93.1-96.8%
~4 pts above industry avg
Total Operating Revenue (quarterly, $M)
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue ($M)$6,161M$5,475M$6,550M$5,382M$6,788M$6,101M$6,570M$6,074M
YoY Growth+10.2%+11.4%+0.3%+12.9%
Key trends
Source: Daloopa. All figures linked to source records.

Adj. Operating EPS (quarterly)
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Adj. Op. EPS$1.82$1.68$2.74$2.44$2.14$1.91$3.04$2.30
YoY Growth+17.6%+13.7%+10.9%-5.7%
Key trends
Source: Daloopa

Adj. Operating Earnings (quarterly, $M)
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Adj. Op. Earnings ($M)$579M$531M$860M$765M$673M$599M$952M$719M
YoY Growth+16.2%+12.8%+10.7%-6.0%
Key trends
Source: Daloopa

Operating Cash Flow -- YTD (quarterly, $M)
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
CFO YTD ($M)($723M)($1,336M)($1,448M)($2,464M)$107M$1,584M$3,432M$4,237M
Key trends
Source: Daloopa

Nuclear Capacity Factor -- YTD (%)
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Capacity Factor93.3%95.4%95.0%94.8%94.1%94.8%96.8%93.1%
Key trends
Source: Daloopa

Total Nuclear Generation (quarterly, GWh)
MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Nuclear Gen. (GWh)$45391$45314$45510$45494$45582$45170$46477$45459
YoY Growth+0.4%-0.3%+2.1%-0.1%
Key trends
Source: Daloopa

4-Year Annual Summary
MetricFY2022FY2023FY2024FY2025
Revenue ($M)$24,440M$24,918M$23,568M$25,533M
Revenue YoY+2.0%-5.4%+8.3%
Operating Income ($M)$495M$1,610M$4,352M$3,086M
Adj. Op. EPS$6.28$8.67$9.39
Adj. EPS YoY+38.1%+8.3%
Adj. Op. Earnings ($M)$2,735M$2,944M
GAAP Net Income ($M)($160M)$1,623M
Adj. EBITDA ($M)$2,667M$4,025M
CFO ($M)($2,353M)($5,301M)($2,464M)$4,237M
Nuclear Gen. (GWh)$173350$174047$181711$182690
Nuclear Capacity Factor94.8%94.4%94.6%94.7%
Nuclear Capacity (MW)$20895$22070$22068$22069
Key trends
Source: Daloopa

Street Consensus Estimates
MetricFY2025AFY2026E
Adj. Operating EPS$9.39$11.00-$12.00 (guidance); ~$11.63 (cons, 25 analysts)
Adj. EBITDA--~$7.9B (consensus, 19 analysts)
Revenue$25.5B~$27.2B (consensus)
EPS CAGR Target--20%+ through 2029 (mgmt)
Share Buyback Auth.--$5B (not in base CAGR)
Calpine FCF Accretion--$2B+ annually
Sources: Company guidance, sell-side consensus estimates, Daloopa

Score rationale

Adj. Operating EPS compounded at ~22% since FY2023, from $6.28 to $9.39 -- a 50% cumulative increase in two years. The massive CFO swing from ($2.5B) in FY2024 to +$4.2B in FY2025 reflects the hedging book unwind and marks a structural inflection to sustainable free cash flow generation. The nuclear fleet operates consistently above 94% capacity factor, ~4 points above the industry average, providing a reliable earnings base.

The Calpine combination adds significant gas/geothermal earnings and at least $2B annual incremental FCF, while management targets 20%+ base EPS CAGR through 2029 -- with no buyback assumed. FY2026 guidance of $11-$12 Adj. Operating EPS includes ~$2 of Calpine accretion. Q4 2025 showed some YoY softness in Adj. EPS (-5.7%), driven by timing items (stock compensation, ZEC seasonality), not structural deterioration. Revenue growth is modest but appropriate for a generation company with pass-through dynamics.

Score: 8/10 -- Strong and accelerating financial trajectory with a real FCF inflection, but the revenue growth profile is inherently lower than high-growth tech and the Q4 2025 EPS softness warrants monitoring. The 20%+ EPS CAGR target and Calpine accretion provide a clear path to continued earnings compounding.


Data sourced from Daloopa, company filings, and sell-side consensus estimates.